Structure Therapeutics recently reported strong Phase 2b results for its oral weight-loss candidate aleniglipron, secured a major GLP‑1 licensing deal, and closed a public offering that raised about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback